GSK pulls plans to mar­ket ane­mia drug in EU and oth­er mar­kets, cit­ing 're­duced op­por­tu­ni­ty'

It ap­pears GSK’s Jes­du­vroq will not launch in new mar­kets for now, with the phar­ma gi­ant with­draw­ing its bid to mar­ket the ane­mia drug in Eu­rope as well as ceas­ing fil­ing in oth­er ter­ri­to­ries.

GSK dis­closed in its sec­ond quar­ter earn­ings an­nounce­ment that it’s de­cid­ed not to com­mer­cial­ize Jes­du­vroq (dapro­du­s­tat) in Eu­rope for the treat­ment of ane­mia among chron­ic kid­ney dis­ease pa­tients. While the EMA’s CHMP did rec­om­mend its use in pa­tients on chron­ic main­te­nance dial­y­sis, it ex­clud­ed those who are not de­pen­dent on dial­y­sis — a “sig­nif­i­cant re­duc­tion in the size of the op­por­tu­ni­ty,” ac­cord­ing to the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER